Article

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection Therapy

2024-10-22

Abstract excerpt

<title>Abstract</title> <p>Autologous stem cell transplantation (ASCT) has been the prime consolidative strategy to increase the depth and duration of response in newly diagnosed multiple myeloma (NDMM), albeit with short- and long-term toxicities. Minimal residual disease (MRD) is an important early response endpoint correlating with clinically meaningful outcomes and may be used to isolate the effect of ASCT. W...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 44756051-814f-5cc2-8e0f-eeca76200772
DOI: 10.21203/rs.3.rs-5015478/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapyDOI 10.21203/rs.3.rs-5015478/v1Read

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple MyelomaSemantic proximity Read

The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?Semantic proximity Read

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsSemantic proximity Read

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read

The future of autologous stem cell transplantation in myelomaSemantic proximity Read

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity Read